The obesity treatment landscape continues to evolve rapidly as demand for GLP-1--based therapies remains strong and competition intensifies. Novo Nordisk's December 2025 FDA approval of Wegovy(R) ...

Semaglutide, the active ingredient in the anti-obesity drug Wegovy, offers cardiovascular benefits for patients without diabetes who have established heart disease, but price reductions would be ...

The higher dosage was shown to help the average patient lose 21% of their body weight ...

By Rishika Sadam and Sriparna Roy HYDERABAD, Feb 17 (Reuters) - Indian drugmaker Dr Reddy’s Laboratories hopes to launch a ...

Novo's lawsuit comes less than one week after Hims & Hers announced plans to sell a compounded version of Novo's weight-loss ...

Wegovy, a weight-loss drug that helps people slim down, is bulking up for its first appearance in the Super Bowl. Novo Nordisk, the drug’s manufacturer, purchased enough ad time from NBC to run a ...

Feb 11 (Reuters) - Novo Nordisk said on Wednesday it plans to launch its weight-loss pill Wegovy in vials. "We are exploring ...

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill Wegovy.

A batch of untitled letters posted on the FDA’s database in recent days takes aim at what the agency has termed “false or misleading” drug ads from the likes of Novo Nordisk, argenx and Sobi. | A ...

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two ...

Novo Nordisk said Wednesday that demand for its Wegovy pill got off to a strong start after it launched in the U.S. in early January ...

Novo’s 90-second ad features a coterie of celebs promoting the oral version of its blockbuster weight loss drug Wegovy.